DR info

Clinical trials : 305 / Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188

Drugs and their primary sponsors and trial info

00305800
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 3   EUCTR2016-001948-19-IT   Argentina;Australia;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden;
13-valent pneumococcal conjugate vaccine
   Region Skane
      2016   Phase 4   NCT03762824   -
1643368-58-4
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
18F-FDG
   GlaxoSmithKline
      2016   -   NCT02899377   United Kingdom;
23-valent pneumococcal polysaccharide vaccine
   Region Skane
      2016   Phase 4   NCT03762824   -
552-02
   Parion Sciences
      2009   Phase 2   NCT00852839   United States;
ABBV-323
   AbbVie Deutschland GmbH & Co. KG
      2020   Phase 2   EUCTR2019-003131-31-NL   Netherlands;
ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED
   Rigshospitalet-Glostrup
      2020   Phase 2   EUCTR2020-002804-38-DK   Denmark;
AMG 557/MEDI5872
   MedImmune LLC
      2015   Phase 2   NCT02334306   France;Sweden;United Kingdom;United States;
   MedImmune, LLC
      2015   Phase 2   EUCTR2014-003896-41-GB   France;Sweden;United Kingdom;United States;
ASCs
   Rigshospitalet, Denmark
      2020   Phase 2   NCT04615455   Denmark;
Abatacept
   Bristol-Myers Squibb
      2020   Phase 2   NCT04186871   Argentina;Australia;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2016   Phase 3   NCT02915159   Argentina;Australia;Brazil;Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Puerto Rico;Sweden;United States;
   The Cleveland Clinic
      2013   Phase 2   NCT02027298   United States;
   University Medical Center Groningen
      2014   -   EUCTR2014-000417-31-NL   Netherlands;
Abatacept Placebo
   Bristol-Myers Squibb K.K.
      2017   Phase 3   JPRN-JapicCTI-173521   -
Abatacept SC
   University Medical Center Groningen
      2014   Phase 3   NCT02067910   Netherlands;
Acycloguanosine
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy;
Alginate
   Teikyo University
      2009   -   JPRN-UMIN000029307   Japan;
Allogeneic Mesenchymal Stem Cells (AlloMSC)
   The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
      2009   Phase 1/Phase 2   NCT00953485   China;
Allogeneic Stem Cell Transplant
   Northwestern University
      2003   Phase 1   NCT00278512   United States;
Allogeneic adipose tissue-derived stromal/stem cells
   Rigshospitalet-Glostrup
      2020   Phase 2   EUCTR2020-002804-38-DK   Denmark;
Aloe vera
   Cairo University
      2021   Phase 3   NCT04252209   -
Anti-pandemic H1N1 influenza vaccine
   University of Sao Paulo
      2010   Phase 4   NCT01151644   Brazil;
Arava
   ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS
      2021   Phase 2   EUCTR2019-002470-32-IT   France;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
Artificial Saliva
   Pontificia Universidad Catolica de Chile
      2006   Phase 4   NCT00438048   Chile;
Assigned Interventions CD19/BCMA CAR T-cells
   Zhejiang University
      2021   Early Phase 1   NCT05085431   China;
Autologous Serum
   Pontificia Universidad Catolica de Chile
      2018   Phase 3   NCT03436576   Chile;
Autologous Stem Cell Transplant
   Northwestern University
      2003   Phase 1   NCT00278512   United States;
Autologous serum
   Hospital Nacional Profesor Alejandro Posadas
      2017   Phase 4   NCT03608761   Argentina;
Aún no establecido
   Novartis Farmacéutica, S.A.
      2019   Phase 2   EUCTR2018-004387-54-ES   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Jordan;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States;
B / Phuket / 3073/2013-like virus)
   University of Sao Paulo General Hospital
      2018   Phase 4   NCT03540823   Brazil;
BENLYSTA - 120 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 120 MG 1 FLACONCINO
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2016   Phase 2   EUCTR2015-000400-26-IT   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
BMS-188667
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
   University Medical Center Groningen
      2014   -   EUCTR2014-000417-31-NL   Netherlands;
BMS-931699
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
   Bristol-Myers Squibb
      2016   Phase 2   NCT02843659   Australia;Chile;Colombia;France;Hungary;Italy;Mexico;Peru;Poland;Puerto Rico;Russian Federation;South Africa;United States;
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
BMS-986142
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
   Bristol-Myers Squibb
      2016   Phase 2   NCT02843659   Australia;Chile;Colombia;France;Hungary;Italy;Mexico;Peru;Poland;Puerto Rico;Russian Federation;South Africa;United States;
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
BMS-986195
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
BMS-986325
   Bristol-Myers Squibb
      2021   Phase 1   NCT04684654   Germany;
BMS986142
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
BMS986195
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
BTK Inhibitor
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
BUPI5
   Clinical Research Centre, Hvidovre University Hospital
      2012   Phase 2   EUCTR2011-006196-19-DK   Denmark;
BUPIVACAINE HYDROCHLORIDE
   Clinical Research Centre, Hvidovre University Hospital
      2012   Phase 2   EUCTR2011-006196-19-DK   Denmark;
Baminercept
   National Institute of Allergy and Infectious Diseases (NIAID)
      2012   Phase 2   NCT01552681   United States;
Baricitinib
   Peking Union Medical College Hospital
      2021   Phase 2   NCT05016297   China;
      2020   Phase 1/Phase 2   NCT04916756   China;
Belimumab
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2009   -   EUCTR2009-015978-35-FR   France;
   Assistance Publique - Hôpitaux de Paris
      2010   Phase 2   NCT01160666   France;
   GlaxoSmithKline
      2016   Phase 2   NCT02631538   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
Benlysta (Belimumab)
   GlaxoSmithKline R&D Ltd
      2017   Phase 2   EUCTR2015-000400-26-GB   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2016   Phase 2   EUCTR2015-000400-26-NO   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2015   Phase 2   EUCTR2015-000400-26-SE   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2015   Phase 2   EUCTR2015-000400-26-NL   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2015   Phase 2   EUCTR2015-000400-26-FR   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2015   Phase 2   EUCTR2015-000400-26-DE   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
   GlaxoSmithKline, S.A.
      2015   Phase 2   EUCTR2015-000400-26-ES   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
Biopsy of the labial salivary gland
   University Hospital, Bordeaux
      2020   -   NCT03841318   France;
Blood sample
   University Hospital, Bordeaux
      2020   -   NCT03841318   France;
   University Hospital, Limoges
      2010   -   NCT01081184   France;
Branebrutinib
   Bristol-Myers Squibb
      2020   Phase 2   NCT04186871   Argentina;Australia;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
Bupivacaine
   Hvidovre University Hospital
      2012   Phase 2   NCT01584947   Denmark;
Bupizenge
   Clinical Research Centre, Hvidovre University Hospital
      2012   Phase 2   EUCTR2011-006196-19-DK   Denmark;
CDZ173
   Novartis Pharma Services AG
      2016   Phase 2   EUCTR2014-004616-12-PL   Germany;Hungary;Poland;
      2016   Phase 2   EUCTR2014-004616-12-HU   Germany;Hungary;Poland;
      2016   Phase 2   EUCTR2014-004616-12-DE   Germany;Hungary;Poland;
   Novartis Pharmaceuticals
      2016   Phase 2   NCT02775916   Germany;Hungary;
CFZ533
   NOVARTIS PHARMA AG
      2021   Phase 2   EUCTR2020-001942-20-IT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
   Novartis Pharma AG
      2021   Phase 2   EUCTR2020-001942-20-PT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-001942-20-NL   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-001942-20-DE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2020   Phase 2   EUCTR2020-001942-20-HU   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2020   Phase 2   EUCTR2020-001942-20-GR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-004476-35-SE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-004476-35-NL   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-004476-35-GB   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004476-35-SI   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004476-35-PT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004476-35-IT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004476-35-HU   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004476-35-GR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004476-35-FR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004476-35-DE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004476-35-AT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
   Novartis Pharma Services AG
      2016   Phase 2   EUCTR2013-004808-19-DE   Germany;Hungary;Switzerland;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-004808-19-HU   Germany;Hungary;Switzerland;United Kingdom;
      2014   Phase 2   EUCTR2013-004808-19-GB   Germany;Hungary;Switzerland;United Kingdom;United States;
   Novartis Pharmaceuticals
      2019   Phase 2   NCT03905525   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
CFZ533 (iscalimab)
   Novartis Pharmaceuticals
      2021   Phase 2   NCT04541589   Austria;France;Germany;Greece;Hungary;Israel;Japan;Netherlands;Portugal;Russian Federation;Turkey;
CFZ533 active - Cohort 1
   Novartis Pharmaceuticals
      2014   Phase 2   NCT02291029   Germany;Hungary;Switzerland;United Kingdom;United States;
CFZ533 active - Cohort 2
   Novartis Pharmaceuticals
      2014   Phase 2   NCT02291029   Germany;Hungary;Switzerland;United Kingdom;United States;
CFZ533 active - Cohort 3
   Novartis Pharmaceuticals
      2014   Phase 2   NCT02291029   Germany;Hungary;Switzerland;United Kingdom;United States;
CFZ533 active -Cohort 3
   Novartis Pharmaceuticals
      2014   Phase 2   NCT02291029   Germany;Hungary;Switzerland;United Kingdom;United States;
CO
   Oita University Faculty of Medicine
      2013   -   JPRN-UMIN000010796   Japan;
COVID-19 Vaccine AstraZeneca suspension for injection COVID-19 Vaccine (ChAdOx1-S [recombinant])
   University Medical Center Groningen
      2021   Phase 4   EUCTR2021-001414-10-NL   Netherlands;
COVID-19 Vaccine Janssen suspension for injection COVID-19 vaccine (Ad26.COV2-S [recombinant])
   University Medical Center Groningen
      2021   Phase 4   EUCTR2021-001414-10-NL   Netherlands;
CSCC_ASC(22)
   Rigshospitalet-Glostrup
      2020   Phase 2   EUCTR2020-002804-38-DK   Denmark;
Calcium carbonate D
   Peking University People's Hospital
      2015   Phase 4   NCT02370550   China;
Carbomer
   TRB CHEMEDICA INTERNATIONAL SA
      2008   Phase 3   EUCTR2007-001708-19-GB   France;United Kingdom;
Carbomer 974P
   TRB CHEMEDICA INTERNATIONAL SA
      2007   -   EUCTR2007-001708-19-FR   France;United Kingdom;
Cathepsin S
   F. Hoffmann-La Roche Ltd
      2016   Phase 2   EUCTR2015-004476-30-FR   France;Germany;Italy;Poland;Portugal;United Kingdom;United States;
Cathepsin S Inhibitor
   F. Hoffmann-La Roche Ltd
      2016   Phase 2   EUCTR2015-004476-30-DE   France;Germany;Italy;Poland;Portugal;United Kingdom;United States;
Cathepsin S inhibitor
   F. Hoffmann-La Roche Ltd
      2016   Phase 2   EUCTR2015-004476-30-PT   France;Germany;Poland;Portugal;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-004476-30-PL   France;Germany;Poland;Portugal;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-004476-30-GB   France;Germany;Poland;Portugal;United Kingdom;United States;
Cenegermin
   DOMPé FARMACEUTICI S.P.A.
      2021   Phase 3   EUCTR2021-003749-39-IT   Italy;United States;
Cevimeline
   Department of Dentistry and Oral Surgery, Tochigi National Hospital
      2008   Phase 1   JPRN-UMIN000000997   Japan;
   The Affiliated Huai'an Hospital of Xuzhou Medical University
      2020   Phase 0   ChiCTR2000033420   China;
Citric Acid based Mouthwash
   Grupo de Investigação em Bioquímica e Biologia Oral
      2013   Phase 4   NCT03578900   -
Coconut
   Cairo University
      2021   Phase 3   NCT04252209   -
Comirnaty concentrate for dispersion for injection
   University Medical Center Groningen
      2021   Phase 4   EUCTR2021-001414-10-NL   Netherlands;
Cryostor CS10
   Rigshospitalet, Denmark
      2020   Phase 2   NCT04615455   Denmark;
CsA
   Peking University People's Hospital
      2015   -   ChiCTR-IPR-15005990   China;
Cyclosporin
   Hospital Hietzing
      2020   -   NCT04597762   Austria;
Cyclosporin A
   National Eye Institute (NEI)
      1997   Phase 2   NCT00001731   United States;
   Peking University People's Hospital
      2015   Phase 4   NCT02370550   China;
Cyclosporine A
   Charite University, Berlin, Germany
      2010   Phase 2   NCT01693393   Germany;
Cyclosporine Ophthalmic Solution
   Center for Ophthalmic and Vision Research, LLC
      2021   Phase 4   NCT04835623   United States;
Cyclosporins
   Pavly Moawd
      2018   Phase 3   NCT03865888   Egypt;
Dehydroepiandrosterone
   Helsinki University
      2003   Phase 4   NCT00543166   Finland;
   National Institute of Dental and Craniofacial Research (NIDCR)
      1997   Phase 2   NCT00001598   United States;
   UMC Utrecht
      2000   Phase 2   NCT00391924   Netherlands;
Dexamethasone Parotid Irrigation
   National Institute of Dental and Craniofacial Research (NIDCR)
      2011   Phase 2   NCT01316770   United States;
Diquafosol
   Keio University School of Medicine
      2014   -   JPRN-UMIN000013234   Japan;
Dornase alfa
   UConn Health
      2011   Phase 1   NCT01357447   United States;
E4
   Erasmus MC
      2008   -   EUCTR2007-003537-16-NL   Netherlands;
Estetrol
   Erasmus MC
      2008   -   EUCTR2007-003537-16-NL   Netherlands;
Etanercept
   National Institute of Dental and Craniofacial Research (NIDCR)
      1999   Phase 2   NCT00001954   United States;
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy;
FMP-30
   University of Miami
      2019   Phase 1   NCT03926286   United States;
Filgotinib
   Gilead Sciences
      2017   Phase 2   NCT03100942   Poland;Spain;United Kingdom;United States;
Fm, SH, AS
   Jinyang Li
      2013   -   NCT02147509   China;
Fm, SH, CsA
   Jinyang Li
      2013   -   NCT02147509   China;
G1567970
   Galapagos NV
      2021   Phase 2   EUCTR2020-003298-22-HU   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom;
      2021   Phase 2   EUCTR2020-003298-22-GR   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom;
      2021   Phase 2   EUCTR2020-003298-22-FR   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom;
      2021   Phase 2   EUCTR2020-003298-22-ES   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom;
      2021   Phase 2   EUCTR2020-003298-22-DE   France;Germany;Greece;Hungary;Poland;Spain;Ukraine;United Kingdom;
GLPG3970
   Galapagos NV
      2021   Phase 2   NCT04700280   France;Germany;Greece;Hungary;Poland;Spain;Ukraine;
      2021   Phase 2   EUCTR2020-003298-22-HU   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom;
      2021   Phase 2   EUCTR2020-003298-22-GR   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom;
      2021   Phase 2   EUCTR2020-003298-22-FR   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom;
      2021   Phase 2   EUCTR2020-003298-22-ES   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom;
      2021   Phase 2   EUCTR2020-003298-22-DE   France;Germany;Greece;Hungary;Poland;Spain;Ukraine;United Kingdom;
GS-4059
   Gilead Sciences, Inc.
      2018   Phase 2   EUCTR2016-003558-34-PL   Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003558-34-GB   Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003558-34-ES   France;Italy;Poland;Spain;United Kingdom;United States;
GS-6034
   Gilead Sciences, Inc.
      2018   Phase 2   EUCTR2016-003558-34-PL   Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003558-34-GB   Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003558-34-ES   France;Italy;Poland;Spain;United Kingdom;United States;
GS-9876
   Gilead Sciences, Inc.
      2018   Phase 2   EUCTR2016-003558-34-PL   Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003558-34-GB   Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003558-34-ES   France;Italy;Poland;Spain;United Kingdom;United States;
GSK2618960
   GlaxoSmithKline
      2017   Phase 2   NCT03239600   United Kingdom;
   GlaxoSmithKline Research & Development Limited
      2017   Phase 2   EUCTR2016-004258-14-GB   United Kingdom;
Glycyrrhiza
   Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2000037057   China;
Gold
   Longyan First Affiliated Hospital of Fujian Medical University
      2021   Phase 0   ChiCTR2100042744   China;
   Tongji Hosipital, Tongji University School of Medicine
      2020   Phase 0   ChiCTR2000035194   China;
HGS1006, LymphoStat-B
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2009   -   EUCTR2009-015978-35-FR   France;
HGS1006, LymphoStat-B, monoclonal anti-BLyS, LSB, BENLYSTA
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2016   Phase 2   EUCTR2015-000400-26-IT   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
   GlaxoSmithKline R&D Ltd
      2017   Phase 2   EUCTR2015-000400-26-GB   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2016   Phase 2   EUCTR2015-000400-26-NO   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2015   Phase 2   EUCTR2015-000400-26-SE   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2015   Phase 2   EUCTR2015-000400-26-NL   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2015   Phase 2   EUCTR2015-000400-26-FR   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2015   Phase 2   EUCTR2015-000400-26-DE   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
   GlaxoSmithKline, S.A.
      2015   Phase 2   EUCTR2015-000400-26-ES   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
HYDROCORTISONE SODIUM PHOSPHATE
   KH Hietzing, Department of Ophthalmology
      2018   Phase 4   EUCTR2017-004929-33-AT   Austria;
HYDROXYCHLOROQUINE SULFATE
   ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS
      2021   Phase 2   EUCTR2019-002470-32-IT   France;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
HrIL-2 active
   Peking University People's Hospital
      2015   Phase 2   NCT02464319   China;
Hyaluronate
   Eye Institute of Xiamen University
      2016   Phase 4 study   ChiCTR-OIB-16007789   China;
   Keio University School of Medicine
      2014   -   JPRN-UMIN000013234   Japan;
Hydrocortisone
   Derk Jan Jager
      2014   -   NCT02112019   Netherlands;
   Hospital Hietzing
      2020   -   NCT04597762   Austria;
Hydroxychloroquine
   Assistance Publique - Hôpitaux de Paris
      2008   Phase 3   NCT00632866   France;
   China-Japan Friendship Hospital
      2020   -   ChiCTR2000037989   China;
   Ege University
      2005   -   NCT00873496   Turkey;
   Kanazawa University Graduate School of Medical Science
      2010   -   JPRN-UMIN000004477   Japan;
   Peking Union Medical College Hospital
      2021   Phase 2   NCT05016297   China;
   Seoul National University Hospital
      2011   Phase 3   NCT01601028   Korea, Republic of;
   Shanghai Tongji Hospital
      2019   Phase 4   ChiCTR1900022696   China;
   Tongji Hospital of Tongji University
      2018   -   ChiCTR1800014623   China;
   University Medical Center Utrecht
      2021   Phase 2   EUCTR2020-001933-11-NL   Netherlands;
   Yueyang Hospital of Integrative Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine
      2014   Phase 1 study   ChiCTR-IPR-14005441   -
Hydroxychloroquine 400mg/d
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 2   NCT05113004   -
IL-2
   The First Hospital of Jilin University
      2020   -   NCT04397107   China;
   the Second Hospital of Shanxi Medical University
      2017   -   ChiCTR-INR-17011220   China;
Ianalumab
   Novartis Pharma AG
      2017   Phase 2   EUCTR2016-003292-22-PT   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003292-22-PL   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003292-22-NL   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003292-22-GB   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003292-22-DE   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003292-22-BE   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003292-22-AT   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States;
   Novartis Pharmaceuticals
      2022   Phase 2   NCT05124925   -
Iguratimod
   Chongqing Hospital of Traditional Chinese Medcine
      2019   -   ChiCTR1900024642   China;
   Jiangsu Simcere Pharmaceutical Co., Ltd.
      2021   Phase 2   NCT04830644   China;
   Peking Union Medical College Hospital
      2017   Phase 1/Phase 2   NCT03023592   China;
   Shanghai Tongji Hospital
      2019   Phase 4   ChiCTR1900022696   China;
   Tianjin Medical University General Hospital
      2019   -   ChiCTR1900021345   China;
Ikervis
   KH Hietzing, Department of Ophthalmology
      2018   Phase 4   EUCTR2017-004929-33-AT   Austria;
Impact
   The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
      2020   Phase 1   ChiCTR2000034924   China;
Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus
   University of Sao Paulo General Hospital
      2018   Phase 4   NCT03540823   Brazil;
Iscalimab
   Novartis Pharma AG
      2020   Phase 2   EUCTR2018-004476-35-SE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-004476-35-NL   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-004476-35-GB   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004476-35-SI   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004476-35-PT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004476-35-IT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004476-35-HU   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004476-35-GR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004476-35-FR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004476-35-DE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004476-35-AT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States;
   Yamada Hiroyuki
      2021   Phase 2   JPRN-jRCT2071200072   Australia;Hungary;Japan;
JNJ-80202135
   JANSSEN CILAG INTERNATIONAL NV
      2021   Phase 2   EUCTR2021-000665-32-IT   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States;
   Janssen-Cilag International NV
      2022   Phase 2   EUCTR2021-000665-32-NL   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States;
      2021   Phase 2   EUCTR2021-000665-32-PT   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States;
      2021   Phase 2   EUCTR2021-000665-32-ES   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States;
      2021   Phase 2   EUCTR2021-000665-32-DE   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States;
KCT-0809 ophthalmic solution
   Kissei Pharmaceutical Co., Ltd.
      2016   Phase 3   NCT02503189   Japan;
      2016   Phase 3   NCT02503163   Japan;
      2015   Phase 3   NCT02503176   Japan;
Korean Red Ginseng
   Hanyang University
      2019   -   NCT03983408   Korea, Republic of;
LO2A eye drops
   Ocuwize LTD
      2018   Phase 4   NCT03319420   Israel;
LOU064
   Novartis Farmacéutica, S.A.
      2019   Phase 2   EUCTR2018-004387-54-ES   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Jordan;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States;
   Novartis Pharma AG
      2021   Phase 2   EUCTR2018-004387-54-BG   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Jordan;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004387-54-HU   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Jordan;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004387-54-GB   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Jordan;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004387-54-DK   Australia;Belgium;Brazil;Bulgaria;China;Czechia;Denmark;Estonia;France;Germany;Hungary;Italy;Japan;Lithuania;Netherlands;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004387-54-DE   Australia;Belgium;Brazil;Bulgaria;China;Czechia;Denmark;Estonia;France;Germany;Hungary;Italy;Japan;Lithuania;Netherlands;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004387-54-BE   Australia;Belgium;Brazil;Bulgaria;China;Czechia;Denmark;Estonia;France;Germany;Hungary;Italy;Japan;Lithuania;Netherlands;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
   Novartis Pharmaceuticals
      2019   Phase 2   NCT04035668   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Spain;Switzerland;Taiwan;United Kingdom;United States;
LY3090106
   Eli Lilly and Company
      2015   Phase 1   NCT02614716   Bulgaria;Georgia;Romania;United States;
Lacripep
   TearSolutions, Inc.
      2017   Phase 1/Phase 2   NCT03226444   United States;
Lacryvisc
   TRB CHEMEDICA INTERNATIONAL SA
      2007   -   EUCTR2007-001708-19-FR   France;United Kingdom;
Lanraplenib
   Gilead Sciences
      2017   Phase 2   NCT03100942   Poland;Spain;United Kingdom;United States;
Leflunomide
   University Medical Center Utrecht
      2021   Phase 2   EUCTR2020-001933-11-NL   Netherlands;
Leflunomide 20mg/d
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 2   NCT05113004   -
Leniolisib
   Novartis Pharma Services AG
      2016   Phase 2   EUCTR2014-004616-12-PL   Germany;Hungary;Poland;
      2016   Phase 2   EUCTR2014-004616-12-HU   Germany;Hungary;Poland;
      2016   Phase 2   EUCTR2014-004616-12-DE   Germany;Hungary;Poland;
Levocarnitine
   Vanderbilt University Medical Center
      2021   Phase 2   NCT03953703   United States;
Levofloxacin
   The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
      2020   Phase 1   ChiCTR2000034924   China;
Licorice
   Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2000037057   China;
LimphoStat-B
   University of Udine
      2009   Phase 2   NCT01008982   Italy;
Lipitor®
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy;
Liposic
   LanZhou University
      2018   -   NCT03434106   China;
   Tung Wah Hospital
      2017   -   NCT03060005   China;
M281
   JANSSEN CILAG INTERNATIONAL NV
      2021   Phase 2   EUCTR2021-000665-32-IT   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States;
   Janssen-Cilag International NV
      2022   Phase 2   EUCTR2021-000665-32-NL   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States;
      2021   Phase 2   EUCTR2021-000665-32-PT   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States;
      2021   Phase 2   EUCTR2021-000665-32-ES   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States;
      2021   Phase 2   EUCTR2021-000665-32-DE   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States;
MABTHERA - 1 FIALA 500 MG 50 ML
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2016   Phase 2   EUCTR2015-000400-26-IT   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
MEDI4920
   Viela Bio, Inc.
      2020   Phase 2   EUCTR2019-002713-19-PL   Argentina;China;France;Greece;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Spain;Turkey;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002713-19-HU   Argentina;China;France;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Taiwan;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002713-19-GB   Argentina;China;France;Greece;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Turkey;United Kingdom;United States;
METILPREDNISOLONE
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2016   Phase 2   EUCTR2015-000400-26-IT   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
MHV370
   Novartis Farmacéutica, S.A.
      2021   Phase 2   EUCTR2020-004937-19-ES   China;Germany;Hungary;Israel;Poland;Spain;Switzerland;Taiwan;United Kingdom;
   Novartis Pharma AG
      2021   Phase 2   EUCTR2020-004937-19-HU   China;Germany;Hungary;Israel;Poland;Spain;Switzerland;Taiwan;United Kingdom;
      2021   Phase 2   EUCTR2020-004937-19-DE   China;Germany;Hungary;Israel;Poland;Spain;Switzerland;Taiwan;United Kingdom;
   Novartis Pharmaceuticals
      2021   Phase 2   NCT04988087   China;Germany;Hungary;Spain;United Kingdom;
MICOFENOLATO MOFETILE
   ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS
      2021   Phase 2   EUCTR2019-002470-32-IT   France;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
MRI Imaging with intravenous contrast with gadoterate meglumine
   GlaxoSmithKline
      2016   -   NCT02899377   United Kingdom;
MRNA COVD19 vaccine
   Mayo Clinic
      2021   Early Phase 1   NCT04839315   United States;
MabThera (Rituximab)
   GlaxoSmithKline R&D Ltd
      2017   Phase 2   EUCTR2015-000400-26-GB   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2016   Phase 2   EUCTR2015-000400-26-NO   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2015   Phase 2   EUCTR2015-000400-26-SE   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2015   Phase 2   EUCTR2015-000400-26-NL   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2015   Phase 2   EUCTR2015-000400-26-FR   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2015   Phase 2   EUCTR2015-000400-26-DE   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
   GlaxoSmithKline, S.A.
      2015   Phase 2   EUCTR2015-000400-26-ES   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
   University of Leeds
      2010   -   EUCTR2010-021430-64-GB   United Kingdom;
MabThera (rituximab)
   University of Copenhagen
      2007   Phase 2   NCT00426543   Denmark;
   University of Leeds
      2010   -   EUCTR2010-021430-64-GB   United Kingdom;
Maxidex
   Alcon Research
      2008   Phase 4   NCT00631358   Canada;
Methotrexate
   GlaxoSmithKline
      2017   Phase 2   NCT03239600   United Kingdom;
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy;
Methyl cellulose
   Cairo University
      2021   Phase 3   NCT04252209   -
MighTeaFlow
   Augusta University
      2011   Phase 1/Phase 2   NCT01647737   United States;
Minor Salivary gland (labial) biopsy
   GlaxoSmithKline
      2016   -   NCT02899377   United Kingdom;
Mirabegron
   China Medical University Hospital
      2021   Phase 4   NCT04909255   Taiwan;
Mizoribine
   Graduate School of Medicine, Chiba University
      2013   Phase 2   JPRN-UMIN000004237   Japan;
Mucosta
   Kanazawa Medical University
      2012   -   JPRN-UMIN000008427   Japan;
   Kyoto Prefectural University of Medicine
      2015   -   JPRN-UMIN000019009   Japan;
Mycophenolate mofetil
   Kaohsiung Medical University
      2016   Phase 2   NCT02691949   -
Mycophenolate mofetil 2000mg/d
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 2   NCT05113004   -
Mycophenolate mofetil TEVA
   ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS
      2021   Phase 2   EUCTR2019-002470-32-IT   France;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
Mycophenolate sodium
   University Hospital Muenster
      2005   Phase 1   NCT00542763   Germany;
N-acetylcysteine syrup
   University of Sao Paulo General Hospital
      2021   -   NCT04793646   Brazil;
NGX267
   TorreyPines Therapeutics
      2008   Phase 2   NCT00637793   United States;
NaCl 0,
   University Hospital, Strasbourg, France
      2019   Phase 3   NCT03700138   France;
Nipocalimab
   JANSSEN CILAG INTERNATIONAL NV
      2021   Phase 2   EUCTR2021-000665-32-IT   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States;
   Janssen Research & Development, LLC
      2021   Phase 2   NCT04968912   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States;
   Janssen-Cilag International NV
      2022   Phase 2   EUCTR2021-000665-32-NL   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States;
      2021   Phase 2   EUCTR2021-000665-32-PT   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States;
      2021   Phase 2   EUCTR2021-000665-32-ES   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States;
      2021   Phase 2   EUCTR2021-000665-32-DE   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States;
   Numaguchi Hirotaka
      2022   Phase 2   JPRN-jRCT2031210484   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States Of America;
Nivolumab
   National Cancer Institute (NCI)
      2019   Phase 1   NCT03816345   Canada;United States;
ORENCIA 125 mg solution for injection in pre-filled syringe
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
OSE-127
   Institut de Recherches Internationales Servier
      2021   Phase 2   EUCTR2020-001526-59-DE   Australia;Canada;France;Germany;Hungary;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2020-001526-59-HU   Australia;Canada;France;Germany;Hungary;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2020-001526-59-GB   Australia;Canada;France;Germany;Hungary;Spain;United Kingdom;United States;
Omalizumab
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2014   Phase 1   NCT01716312   United States;
Omega 3 fatty acid
   Hawler Medical University
      2021   Phase 2/Phase 3   NCT05005806   Iraq;
Ophthalmic Emulsion
   Allergan
      2001   Phase 3   NCT00025818   United States;
Orencia
   Arthritis & Rheumatism Associates, P.C.
      2016   Phase 2   NCT03411850   United States;
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 3   EUCTR2016-001948-19-IT   Argentina;Australia;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden;
   Bristol-Myers Squibb International Corporation
      2017   Phase 3   EUCTR2016-001948-19-SE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden;
      2016   Phase 3   EUCTR2016-001948-19-FR   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden;
      2016   Phase 3   EUCTR2016-001948-19-CZ   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden;
   University Medical Center Groningen
      2014   -   EUCTR2014-000417-31-NL   Netherlands;
      2010   -   EUCTR2009-015558-40-NL   Netherlands;
Oxybutynin, tolterodine, solifenacin
   China Medical University Hospital
      2021   Phase 4   NCT04909255   Taiwan;
P-552
   Parion Sciences
      2010   Phase 1/Phase 2   NCT01369589   United States;
PAH
   Guangdong Provincial People's Hospital
      2020   -   ChiCTR2000030342   China;
PARACETAMOLO
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2016   Phase 2   EUCTR2015-000400-26-IT   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
PLAQUENIL
   ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS
      2021   Phase 2   EUCTR2019-002470-32-IT   France;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
PRP injection
   Universidad Nacional de Colombia
      2014   Phase 3   NCT02257957   -
Parsaclisib
   Incyte Corporation
      2019   Phase 2   NCT03627065   United States;
Pilocarpine
   Department of Pediatrics, Graduate School of Medicine, Chiba Univerity
      2008   -   JPRN-UMIN000001460   Japan;
   Oita University Faculty of Medicine
      2013   -   JPRN-UMIN000010796   Japan;
   Pontificia Universidad Catolica de Chile
      2006   Phase 4   NCT00438048   Chile;
   Teikyo University
      2009   -   JPRN-UMIN000029307   Japan;
Pilocarpine Hydrochloride
   Federal University of São Paulo
      2005   Phase 3   NCT04470479   Brazil;
Placebo
   Otsuka Pharmaceutical Co., Ltd.
      2005   Phase 2   JPRN-JapicCTI-050036   Japan;
Plaquenil
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2008   -   EUCTR2007-005218-38-FR   France;
   UMC Utrecht
      2015   -   EUCTR2014-003140-12-NL   Netherlands;
   University Medical Center Utrecht
      2021   Phase 2   EUCTR2020-001933-11-NL   Netherlands;
Prednisone
   Chongqing Hospital of Traditional Chinese Medcine
      2019   -   ChiCTR1900024642   China;
   Peking University People's Hospital
      2015   Phase 4   NCT02370550   China;
   Yueyang Hospital of Integrated Medicine affiliated to Shanghai University of Tradition Chinese Medicine
      2017   -   ChiCTR-INR-16009629   China;
Privigen 100 mg/ml, solution pour perfusion
   Hôpitaux Universitaires de Strasbourg
      2019   Phase 3   EUCTR2017-001371-24-FR   France;
Privigen® 100mg/ml at the dose of 2g/kg of body weight
   University Hospital, Strasbourg, France
      2019   Phase 3   NCT03700138   France;
Probiotic Product - Cap
   Cairo University
      2018   Phase 1/Phase 2   NCT03840538   Egypt;
RC18
   RemeGen Co., Ltd.
      2019   Phase 2   NCT04078386   China;
RO545-9072/F03
   F. Hoffmann-La Roche Ltd
      2016   Phase 2   EUCTR2015-004476-30-PT   France;Germany;Poland;Portugal;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-004476-30-PL   France;Germany;Poland;Portugal;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-004476-30-GB   France;Germany;Poland;Portugal;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-004476-30-FR   France;Germany;Italy;Poland;Portugal;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-004476-30-DE   France;Germany;Italy;Poland;Portugal;United Kingdom;United States;
RO5459072
   F. Hoffmann-La Roche Ltd
      2016   Phase 2   EUCTR2015-004476-30-PT   France;Germany;Poland;Portugal;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-004476-30-PL   France;Germany;Poland;Portugal;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-004476-30-GB   France;Germany;Poland;Portugal;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-004476-30-FR   France;Germany;Italy;Poland;Portugal;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-004476-30-DE   France;Germany;Italy;Poland;Portugal;United Kingdom;United States;
   Hoffmann-La Roche
      2016   Phase 2   NCT02701985   France;Germany;Poland;Portugal;United Kingdom;United States;
RSLV-132
   Resolve Therapeutics
      2017   Phase 2   NCT03247686   United Kingdom;
   Resolve Therapeutics, LLC
      2016   Phase 2   EUCTR2016-001586-87-GB   United Kingdom;
Raptiva
   National Institute of Dental and Craniofacial Research (NIDCR)
      2006   Phase 2   NCT00344448   United States;
Raptiva 100 mg/ml powder and solvent for solution for injection
   Merck Serono International S.A.
      2009   -   EUCTR2007-001377-28-PT   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-NL   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-FR   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-DE   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-AT   Austria;France;Germany;Netherlands;Portugal;
Ravagalimab
   AbbVie Deutschland GmbH & Co. KG
      2020   Phase 2   EUCTR2019-003131-31-NL   Netherlands;
Rebamipide
   Hospital Nacional Profesor Alejandro Posadas
      2017   Phase 4   NCT03608761   Argentina;
   Keio University School of Medicine
      2014   -   JPRN-UMIN000013234   Japan;
   Otsuka Pharmaceutical Co., Ltd.
      2005   Phase 2   NCT00233363   Japan;
      2005   Phase 2   JPRN-JapicCTI-050036   Japan;
   Tochigi medical center
      2013   Phase 2   JPRN-UMIN000010710   Japan;
   University of Alexandria
      2020   -   NCT01759108   Egypt;
Recombinant Human Nerve Growth Factor (rhNGF)
   DOMPé FARMACEUTICI S.P.A.
      2021   Phase 3   EUCTR2021-003749-39-IT   Italy;United States;
Recombinant form of human nerve growth factor produced in Escherichia Coli.
   DOMPé FARMACEUTICI S.P.A.
      2021   Phase 3   EUCTR2021-003749-39-IT   Italy;United States;
Refresh Endura
   Federal University of São Paulo
      2013   Phase 4   NCT02004067   Brazil;
Remibrutinib
   Novartis Pharma AG
      2021   Phase 2   EUCTR2018-004387-54-BG   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Jordan;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004387-54-GB   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Jordan;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004387-54-DK   Australia;Belgium;Brazil;Bulgaria;China;Czechia;Denmark;Estonia;France;Germany;Hungary;Italy;Japan;Lithuania;Netherlands;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004387-54-DE   Australia;Belgium;Brazil;Bulgaria;China;Czechia;Denmark;Estonia;France;Germany;Hungary;Italy;Japan;Lithuania;Netherlands;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004387-54-BE   Australia;Belgium;Brazil;Bulgaria;China;Czechia;Denmark;Estonia;France;Germany;Hungary;Italy;Japan;Lithuania;Netherlands;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
Restasis
   Federal University of São Paulo
      2013   Phase 4   NCT02004067   Brazil;
Rituxan (US, Canada, Japan), MabThera (rest of world)
   University of Leeds
      2010   -   EUCTR2010-021430-64-GB   United Kingdom;
Rituximab
   GlaxoSmithKline
      2016   Phase 2   NCT02631538   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2004   Phase 1   NCT00101829   United States;
   Yokohama City University Hospital Department of Pediatrics
      2015   -   JPRN-UMIN000018376   Japan;
Rituximab (anti-CD20)
   University Medical Centre Groningen
      2006   Phase 1/Phase 2   NCT00363350   Netherlands;
Rituximab, Mabthera
   University of Copenhagen
      2007   Phase 2   NCT00426543   Denmark;
S95011
   Institut de Recherches Internationales Servier
      2021   Phase 2   EUCTR2020-001526-59-DE   Australia;Canada;France;Germany;Hungary;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2020-001526-59-HU   Australia;Canada;France;Germany;Hungary;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2020-001526-59-GB   Australia;Canada;France;Germany;Hungary;Spain;United Kingdom;United States;
S95011 concentrate for solution for infusion
   Institut de Recherches Internationales Servier
      2021   Phase 2   NCT04605978   Australia;Canada;France;Germany;Hungary;Spain;United Kingdom;United States;
SA001 High dose
   Samjin Pharmaceutical Co., Ltd.
      2020   Phase 2   NCT05269810   Korea, Republic of;
SA001 Low dose
   Samjin Pharmaceutical Co., Ltd.
      2020   Phase 2   NCT05269810   Korea, Republic of;
SA001 Mid dose
   Samjin Pharmaceutical Co., Ltd.
      2020   Phase 2   NCT05269810   Korea, Republic of;
SALINE
   TRB CHEMEDICA INTERNATIONAL SA
      2007   -   EUCTR2007-001708-19-FR   France;United Kingdom;
SAR441344
   Sanofi
      2020   Phase 2   NCT04572841   Argentina;Belgium;Canada;France;Germany;Hungary;Korea, Republic of;Mexico;Spain;Taiwan;United States;
   Sanofi-Aventis Recherche & Développement
      2020   Phase 2   EUCTR2020-000511-77-HU   Argentina;Belgium;Canada;France;Germany;Hungary;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United States;
      2020   Phase 2   EUCTR2020-000511-77-DE   Argentina;Belgium;Canada;France;Germany;Hungary;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United States;
SOLU MEDROL - 125 MG/2 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE A DOPPIA CAMERA DA 125 MG/2 ML
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2016   Phase 2   EUCTR2015-000400-26-IT   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
SS-1
   Chang Gung Memorial Hospital
      2014   Phase 2   NCT02110446   Taiwan;
   China Medical University Hospital
      2014   Phase 2   NCT02855658   Taiwan;
SVS20
   TRB CHEMEDICA INTERNATIONAL SA
      2008   Phase 3   EUCTR2007-001708-19-GB   France;United Kingdom;
      2007   -   EUCTR2007-001708-19-FR   France;United Kingdom;
Saline
   Derk Jan Jager
      2014   -   NCT02112019   Netherlands;
   UConn Health
      2011   Phase 1   NCT01357447   United States;
Sandimmun Optoral
   Charité Berlin, Department of rheumatology
      -   -   EUCTR2009-013976-38-DE   Germany;
Sialoendoscopy
   Derk Jan Jager
      2014   -   NCT02112019   Netherlands;
Sodium chloride
   TRB CHEMEDICA INTERNATIONAL SA
      2007   -   EUCTR2007-001708-19-FR   France;United Kingdom;
Sodium hyaluronate
   TRB CHEMEDICA INTERNATIONAL SA
      2007   -   EUCTR2007-001708-19-FR   France;United Kingdom;
Softacort
   KH Hietzing, Department of Ophthalmology
      2018   Phase 4   EUCTR2017-004929-33-AT   Austria;
Standard care Hyaluronic acid eye drops
   Universidad Nacional de Colombia
      2014   Phase 3   NCT02257957   -
Sulfate
   China-Japan Friendship Hospital
      2020   -   ChiCTR2000037989   China;
Sulfate d'hydroxychloroquine
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2008   -   EUCTR2007-005218-38-FR   France;
Systane Ultra UD
   Ocuwize LTD
      2018   Phase 4   NCT03319420   Israel;
TACHIPIRINA - 500 MG COMPRESSE20 COMPRESSE
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2016   Phase 2   EUCTR2015-000400-26-IT   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
TCM (Gan-Lu-Yin)GLY
   Chung Shan Medical University
      2016   Phase 2   NCT04111341   Taiwan;
Tacrolimus
   Eye Institute of Xiamen University
      2016   Phase 4 study   ChiCTR-OIB-16007789   China;
   Pavly Moawd
      2018   Phase 3   NCT03865888   Egypt;
   The Eye Hospital of Wenzhou Medical University
      2018   -   ChiCTR-IPR-17013772   China;
   University of Sao Paulo General Hospital
      2010   Phase 4   NCT01850979   Brazil;
Tears Naturale Forte
   LanZhou University
      2018   -   NCT03434106   China;
   Tung Wah Hospital
      2017   -   NCT03060005   China;
Tetracycline
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy;
Thalidomide
   National Institute of Dental and Craniofacial Research (NIDCR)
      1997   Phase 2   NCT00001599   United States;
Thymosin Beta 4 eye drops
   Michigan Cornea Consultants, PC
      2011   Phase 2   NCT01393132   United States;
Tibulizumab (LY3090106)
   Matthew C. Baker
      2021   Phase 2/Phase 3   NCT04563195   United States;
Tirabrutinib
   Gilead Sciences
      2017   Phase 2   NCT03100942   Poland;Spain;United Kingdom;United States;
   Gilead Sciences, Inc.
      2018   Phase 2   EUCTR2016-003558-34-PL   Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003558-34-GB   Poland;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003558-34-ES   France;Italy;Poland;Spain;United Kingdom;United States;
Tivanisiran sodium ophthalmic solution
   Sylentis, S.A.
      2021   Phase 3   NCT04819269   United States;
Tocilizumab
   University Hospital, Strasbourg, France
      2013   Phase 2/Phase 3   NCT01782235   France;
Tofacitinib
   National Institute of Dental and Craniofacial Research (NIDCR)
      2021   Phase 1/Phase 2   NCT04496960   United States;
   Peking University People's Hospital
      2021   Phase 2   NCT05087589   China;
UCB5857
   UCB CELLTECH (UK BRANCH OF UCB PHARMA SA)
      2015   Phase 2   EUCTR2014-004523-51-IT   France;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom;
   UCB Celltech
      2015   Phase 2   NCT02610543   France;Greece;Italy;Spain;Sweden;United Kingdom;
   UCB Celltech, UK
      2017   Phase 2   EUCTR2014-004523-51-GR   France;Greece;Italy;Spain;Sweden;United Kingdom;
      2016   Phase 2   EUCTR2014-004523-51-SE   France;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2015   Phase 2   EUCTR2014-004523-51-GB   France;Greece;Italy;Spain;Sweden;United Kingdom;
      2015   Phase 2   EUCTR2014-004523-51-FR   France;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2015   Phase 2   EUCTR2014-004523-51-ES   France;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom;
Ustekinumab
   University of Rochester
      2020   Phase 1   NCT04093531   United States;
VAY736
   NOVARTIS PHARMA AG
      2017   Phase 2   EUCTR2016-003292-22-IT   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States;
   Novartis Pharma Services AG
      2014   Phase 2   EUCTR2013-000250-22-DE   Germany;
   Novartis Pharmaceuticals
      2017   Phase 2   NCT02962895   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2014   Phase 2   NCT02149420   France;Germany;Netherlands;United States;
VAY736 antibody
   Novartis Farmacéutica, S.A.
      2017   Phase 2   EUCTR2016-003292-22-ES   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States;
   Novartis Pharma AG
      2017   Phase 2   EUCTR2016-003292-22-PT   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003292-22-PL   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003292-22-NL   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003292-22-HU   Argentina;Austria;Belgium;Bulgaria;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003292-22-GB   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003292-22-FR   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003292-22-DE   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003292-22-BE   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003292-22-AT   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States;
VAY736 higher dose
   Novartis Pharmaceuticals
      2015   Phase 1/Phase 2   NCT02495129   Netherlands;
VAY736 lower dose
   Novartis Pharmaceuticals
      2015   Phase 1/Phase 2   NCT02495129   Netherlands;
VIB4920
   VIELABIO Inc.
      2020   Phase 2   EUCTR2019-002713-19-IT   Argentina;China;France;Greece;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Spain;Turkey;United Kingdom;United States;
   Viela Bio
      2019   Phase 2   NCT04129164   France;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;United Kingdom;United States;
   Viela Bio, Inc.
      2020   Phase 2   EUCTR2019-002713-19-PL   Argentina;China;France;Greece;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Spain;Turkey;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002713-19-HU   Argentina;China;France;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Taiwan;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002713-19-GB   Argentina;China;France;Greece;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Turkey;United Kingdom;United States;
VIB7734
   Viela Bio
      2018   Phase 1   NCT03817424   Poland;Spain;United States;
Vehicle Control
   Michigan Cornea Consultants, PC
      2011   Phase 2   NCT01393132   United States;
Vehicle ophthalmic solution
   Sylentis, S.A.
      2021   Phase 3   NCT04819269   United States;
Vitamin A
   Keio University School of Medicine
      2014   -   JPRN-UMIN000013234   Japan;
Vitamin D3
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy;
Water
   Department of Dentistry and Oral Surgery, Tochigi National Hospital
      2008   Phase 1   JPRN-UMIN000000997   Japan;
XYZAL - 20 COMPRESSE RI
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2016   Phase 2   EUCTR2015-000400-26-IT   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
Xeros
   Grupo de Investigação em Bioquímica e Biologia Oral
      2013   Phase 4   NCT03578900   -
Xylitol
   Augusta University
      2011   Phase 1/Phase 2   NCT01647737   United States;
Yellow Fever vaccine (17D)
   University of Sao Paulo General Hospital
      2018   -   NCT03430388   Brazil;